Press release -

ConceptoMed announces Supply Agreement with Becton, Dickinson & Company

ConceptoMed is pleased to announce that it has reached a supply agreement with Becton, Dickinson & Company (BD) – a leading global medical technology company. ConceptoMed will use the different BD syringes in their production of Luer-Jack® - the new generation of medical syringes.

The syringes from BD meet all requirements for upcoming CE- and FDA-approval. ConceptoMed expect to launch Luer-Jack® into European markets before year-end 2015. Luer-Jack® will be commercialized as single packed units - and combined into different applicable custom procedure packs and procedure kits from manufacturers in selected clinical fields, where Luer-Jack® will support Best Practice Procedures.

- A premium product like the Luer-Jack® deserves to be supported by components of high quality and high reliability. BD is a worldwide trusted manufacturer of such high quality medical supplies, and the supply agreement is a sturdy step on the road to establishing Luer-Jack® as a new generation of medical syringes, says CEO of ConceptoMed, Christian Mide.

Luer-Jack® from ConceptoMed is fully compatible with the female “luer slip” and “luer lock” global standard for medical syringes and connections. The patent protected and revolutionary Luer-Jack® is unique, providing Precise Disconnection Power PDP™.

Luer-Jack® PDP™ represents advantages for patients and healthcare professionals in many ways:

  • Prevention of needlestick injuries through OneHand non-recapping needle procedures
  • Aseptic healthcare services by reducing risk of cross-contamination of micro critical aseptic parts
  • Increased operator control and patient safety during needle and catheter placement procedures

Related links

Topics

  • Business enterprise

ConceptoMed AS is a rising Medtech star with innovative product categories, unique patent protected Medtech technology and strong finances. We develop and commercialize smart Medtech solutions for an international market. Excellence through Simplicity! We are brave, curious, dedicated and open-minded. Based in Norway, the team is continuously meeting milestones and expanding its activities for international growth. For more information on the company and career opportunities, see www.conceptomed.com www.myshieldkids.com.

Follow us on MyNewsdesk and LinkedIn.

Luer-Jack® is a registered trademark owned by ConceptoMed AS. The Luer-Jack® technology is widely patent protected throughout the world, currently with almost 30 patents from 5 patent families.

Contacts

  • ConceptoMed announces Supply Agreement with Becton, Dickinson & Company
    ConceptoMed announces Supply Agreement with Becton, Dickinson & Company
    License:
    Media Use
    File format:
    .pdf
    Download
  • ConceptoMed announces Supply Agreement with Becton, Dickinson & Company
    License:
    Media Use
    File format:
    .docx
    Download

Related content

  • New Luer-Jack® Patent Granted - New Generation of Luer Medical Syringes

    The Intellectual Property Office in the United Kingdom has granted approval for a second family of patents surrounding the Luer-Jack® technology. The patent was published on the 27th of May 2015 and is ConceptoMed's third granted patent in a large and growing patent family.

  • UK Patent granted for Luer-Jack™

    Luer-Jack™ is a unique medical syringe, which significantly increases control of the syringe and needles during disconnections. The Intellectual Property Office in the United Kingdom has granted approval for a UK Patent for fluid transfer devices (Luer-Jack™). The patent is ConceptoMed's first granted patent and will be applied to other products in development.

  • Runar Bjørklund appointed COB in ConceptoMed AS – Private Placement of €1.05 Million

    ​The Board of Directors of ConceptoMed AS have the pleasure of announcing the successful completion of a private placement of equity in ConceptoMed AS. Gross proceeds from the private placement amounts to NOK 9.5 Million (€1.05 Million). On Monday 19th of January 2015, Runar Bjørklund, shareholder in ConceptoMed AS and former CFO of Nycomed, was appointed new Chairman of the Board.

  • Oversubscribed Private Placement of €1.42 Million

    The Board of Directors of ConceptoMed AS have the pleasure of announcing the successful completion of a private placement of equity in ConceptoMed AS. The share issue was oversubscribed and provided the company with 12 new shareholders. Gross proceeds from the private placement amounted to NOK 11,550,000 (€1.42 Million)

  • The Intervention Centre, Oslo University Hospital – Final Report Luer-Jack®

    From June 2014 to July 2015, The Norwegian Research Council (VRI) supported an evaluation research study on Luer-Jack®, a new medical syringe with one-hand disconnection from needles/cannulas and luer type connections. The Intervention Centre of Oslo University Hospital has conducted the study, and the final report was submitted to ConceptoMed today, 1st of September 2015.

  • LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark)

    LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark) FIRST ORDERS OF LUER-JACK SHIPPING AFTER CE-MARK APPROVAL ConceptoMed today announced that the company has received CE Mark approval for the Luer-Jack® syringe, a new and innovative medical syringe. Luer-Jack® is now ready for the European market and other large markets, where the CE mark allows for market entry.